Here's How Much You'd Have If You Invested $1000 in Vertex Pharmaceuticals a Decade Ago
https://www.zacks.com/stock/news/2207791/here-s-how-much-you-d-have-if-you-invested-1000-in-vertex-pharmaceuticals-a-decade-ago?cid=CS-ZC-FT-tale_of_the_tape|investing_$1000-2207791
Jan 09, 2024 - Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
0
Vertex (VRTX), CRSP's Casgevy Gets FDA Nod for Thalassemia
https://www.zacks.com/stock/news/2211622/vertex-vrtx-crsp-s-casgevy-gets-fda-nod-for-thalassemia?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2211622
Jan 17, 2024 - This is the second approval granted to Vertex (VRTX)/CRISPR's (CRSP) gene therapy Casgevy and comes just a month after the FDA approved the therapy for sickle cell disease.
0
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
https://www.zacks.com/stock/news/2211744/vertex-pharmaceuticals-vrtx-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2211744
Jan 17, 2024 - Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $433.76, signifying a -0.85% move from its prior day's close.
0
Top Stock Reports for JPMorgan Chase, Salesforce & Vertex Pharmaceuticals
https://www.zacks.com/commentary/2231762/top-stock-reports-for-jpmorgan-chase-salesforce-vertex-pharmaceuticals?cid=CS-ZC-FT-research_daily-2231762
Feb 26, 2024 - Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Salesforce, Inc. (CRM) and Vertex Pharmaceuticals Incorporated (VRTX).
0
GSK vs. VRTX: Which Stock Is the Better Value Option?
https://www.zacks.com/stock/news/2236145/gsk-vs-vrtx-which-stock-is-the-better-value-option?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2236145
Mar 05, 2024 - GSK vs. VRTX: Which Stock Is the Better Value Option?
0
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts
https://www.zacks.com/stock/news/2245680/vertex-pharmaceuticals-vrtx-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2245680
Mar 25, 2024 - In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $416.03, indicating a +0.09% shift from the previous trading day.
0
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
https://www.zacks.com/stock/news/2256355/bluebird-blue-underperforms-industry-ytd-amid-challenges?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2256355
Apr 16, 2024 - bluebird (BLUE) plunges 25% year to date as it struggles to fuel the growth of its complex and expensive gene therapies.
0
GSK vs. VRTX: Which Stock Should Value Investors Buy Now?
https://www.zacks.com/stock/news/2193083/gsk-vs-vrtx-which-stock-should-value-investors-buy-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2193083
Dec 04, 2023 - GSK vs. VRTX: Which Stock Is the Better Value Option?
0
CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline
https://www.zacks.com/stock/news/2193794/crispr-crsp-to-focus-on-next-generation-car-t-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193794
Dec 05, 2023 - Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.
0
BLUE, CRSP & VRTX Down Despite FDA Nod to SCD Therapies
https://www.zacks.com/stock/news/2196355/blue-crsp-vrtx-down-despite-fda-nod-to-scd-therapies?cid=CS-ZC-FT-analyst_blog|industry_focus-2196355
Dec 11, 2023 - The FDA approves two one-time gene therapies for treating sickle cell disease. One of them utilizes the Nobel prize-winning CRISPR/Cas9 gene-editing technology.
0